Safety and efficacy of anlotinib combined with taxane and lobaplatin in neoadjuvant treatment of clinical stage II/III triple-negative breast cancer in China (the neoALTAL trial): a single-arm, phase 2 trialResearch in context

Safety and efficacy of anlotinib combined with taxane and lobaplatin in neoadjuvant treatment of clinical stage II/III triple-negative breast cancer in China (the neoALTAL trial): a single-arm, phase 2 trialResearch in context

Summary: Background: Anlotinib is a new type of tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors 1/2/3, platelet-derived growth factor receptors α/β, and fibroblast growth factor receptors 1–4 and c-Kit, with a broad spectrum of inhibitory effects on tumor angioge...

Full description

Bibliographic Details
Main Authors: Yan Liang, Jing Liu, Jia Ge, Qiyun Shi, Guozhi Zhang, Andi Wan, Tao Luo, Hao Tian, Linjun Fan, Shushu Wang, Li Chen, Peng Tang, Kai Zhu, Jun Jiang, Xiuwu Bian, Yi Zhang, Xiaowei Qi
Format: Article
Language:English
Published: Elsevier 2024-05-01
Series:EClinicalMedicine
Subjects:
Anlotinib
Anti-tumor angiogenesis
Triple-negative breast cancer
Neoadjuvant chemotherapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537024001640

Internet

http://www.sciencedirect.com/science/article/pii/S2589537024001640

Similar Items